文献速递免疫规划

Na-APR-1钩虫疫苗在未感染成人中的安全性与免疫原性

Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults.
PubMed 文献 · Vaccine · 2022-09-14

在美国40名健康且未感染钩虫的成人中开展开放标签剂量递增1期试验,受试者在第0、56、112天肌肉注射30或100 μg重组Na-APR-1(M74),佐剂为氢氧化铝佐剂(Alhydrogel)单用或联合2.5或5.0 μg GLA-AF。疫苗耐受性良好,未观察到与接种相关的严重不良事件或特别关注的不良事件;100 μg组抗原特异性IgG水平显著高于30 μg组,加用GLA-AF后两个抗原剂量组的IgG水平均高于同剂量非GLA佐剂组。

要点

  • 最常见不良事件为轻或中度注射部位压痛和疼痛、轻或中度恶心和头痛。
  • 未观察到与接种相关的严重不良事件或特别关注的不良事件。
  • 100 μg Na-APR-1(M74)组抗原特异性IgG水平显著高于30 μg组。

核心结论

  • 在未感染钩虫的成人中接种重组Na-APR-1(M74)耐受性良好、安全,并诱导针对疫苗抗原Na-APR-1(M74)的显著IgG应答。
  • 基于这些有利结果,该产品已在加蓬和巴西的钩虫流行区启动临床试验。

研究设计与样本

  • 在美国开展的开放标签剂量递增1期临床试验,纳入40名健康、未感染钩虫的成人志愿者。
  • 受试者接受30或100 μg重组Na-APR-1(M74),佐剂为Alhydrogel单用或Alhydrogel联合2.5或5.0 μg水剂型GLA-AF。
  • 研究疫苗于第0、56、112天肌肉注射。

主要发现

  • Na-APR-1(M74)/Alhydrogel耐受性良好;最常见不良事件为轻或中度注射部位压痛和疼痛,以及轻或中度恶心和头痛。
  • 未观察到与接种相关的严重不良事件或特别关注的不良事件。
  • 接受100 μg Na-APR-1(M74)者诱导的抗原特异性IgG抗体水平显著高于接受30 μg抗原者。
  • 在30和100 μg Na-APR-1(M74)组中,加用GLA-AF者针对Na-APR-1(M74)的IgG水平均高于同抗原剂量的非GLA佐剂配方。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Necator americanus hemoglobinase, aspartic protease-1 (Na-APR-1), facilitates the ability of adult hookworms to parasitize the intestine of their human hosts. A recombinant version of APR-1 protected laboratory animals against hookworm infection by inducing neutralizing antibodies that block the protein's enzymatic activity and thereby impair blood feeding. A catalytically inactive version of the wild-type hemoglobinase (Na-APR-1(M74)) was expressed by infiltrating Nicotiana benthamiana tobacco plants with an Agrobacterium tumefaciens strain engineered to express the vaccine antigen, which was adjuvanted with aluminum hydroxide adjuvant (Alhydrogel). METHODS: An open-label dose-escalation Phase 1 clinical trial was conducted in 40 healthy, hookworm-naïve adult volunteers in the United States. Participants received 30 or 100 µg of recombinant Na-APR-1(M74) with Alhydrogel or with Alhydrogel co-administered with one of two doses (2.5 or 5.0 µg) of an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF). Intramuscular injections of study vaccine were administered on days 0, 56, and 112. RESULTS: Na-APR-1(M74)/Alhydrogel was well-tolerated; the most frequent adverse events were mild or moderate injection site tenderness and pain, and mild or moderate nausea and headache. No serious adverse events or adverse events of special interest related to vaccination were observed. Significantly higher levels of antigen-specific IgG antibodies were induced in those who received 100 µg Na-APR-1(M74) than those who received 30 µg of antigen. Adding GLA-AF to Na-APR-1(M74)/Alhydrogel resulted in higher levels of IgG against Na-APR-1(M74) in both the 30 and 100 µg Na-APR-1(M74) groups in comparison to the non-GLA formulations at the same antigen dose. CONCLUSIONS: Vaccination of hookworm-naïve adults with recombinant Na-APR-1(M74) was well-tolerated, safe, and induced significant IgG responses against the vaccine antigen Na-APR-1(M74). Given these favorable results, clinical trials of this product were initiated in hookworm-endemic areas of Gabon and Brazil.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Diemert DJ, Zumer M, Campbell D, et al. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults. Vaccine. 2022. PMID: 36114129. doi:10.1016/j.vaccine.2022.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。